Skip to main content
Clinical Trials/NL-OMON55914
NL-OMON55914
Recruiting
Phase 3

Protecting late-moderate preterm infants from respiratory tract infections and wheeze in their first yearsof life by using bacterial lysates. - PROTEA

Franciscus Gasthuis & Vlietland0 sites500 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
respiratory tract infections and wheezing
Sponsor
Franciscus Gasthuis & Vlietland
Enrollment
500
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Gestational age at delivery between 30\+0 and 35\+6 weeks
  • Postnatal age at least 6 weeks at randomization \& postmenstrual age at least 37
  • Written informed consent by both parents or formal caregivers

Exclusion Criteria

  • Underlying other severe respiratory disease such as broncho\-pulmonary dysplasia
  • (unexpected in this group); hemodynamic significant cardiac disease;
  • immunodeficiency; severe failure to thrive; birth asphyxia with predicted poor
  • neurological out\-come; syndrome or serious congenital disorder.
  • Dysmaturity and/or weight \< 2\.5 kg at age of randomization.
  • Maternal TNF\-alpha inhibitors or other immunosuppression during pregnancy
  • and/or breastfeeding
  • Parents unable to speak and read Dutch/English language
  • Known allergic hypersensitivity to the active ingredients/substance or to any
  • of the excipients.

Outcomes

Primary Outcomes

Not specified

Similar Trials